Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood

Blood

Volumn 103, Issue 7, 2004, Pages 2554-2559

  Hirsch, Betsy ^b   Shimamura, Akiko ^b   Moreau, Lisa ^b   Baldinger, Shari ^b   Hag Alshiekh, Maha ^b   Bostrom, Bruce ^b   Sencer, Susan ^b   D'Andrea, Alan D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BRCA2 GENE; CANCER SUSCEPTIBILITY; CASE REPORT; CHILD; DISEASE ASSOCIATION; FANCD1 GENE; FANCONI ANEMIA; GENE; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; MEDULLOBLASTOMA; NEPHROBLASTOMA; PEDIGREE; PRIORITY JOURNAL; SOLID TUMOR;

EID: 1642315917     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-06-1970     Document Type: Article

References (38)

1. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer. 2003;3:23-34.
2. Joenje H, Patel KJ. The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet. 2001;2:446-457.
3. Kutler DI, Singh B, Satagopan J, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood. 2003;101:1249-1256.
4. Auerbach AD, Allen RG. Leukemia and preleukemia in Fanconi anemia patients. A review of the literature and report of the International Fanconi Anemia Registry. Cancer Genet Cytogenet. 1991;51:1-12.
5. Alter BP, Greene MH, Velazquez I, Rosenberg PS. Cancer in Fanconi anemia [letter]. Blood. 2003;101:2072.
6. Wagner JE, MacMillan ML, Auerbach AD. Hematopoietic cell transplantation for Fanconi anemia. In: Blume KG, Forman SJ, Appelbaum FA, eds. Thomas' Hematopoietic Cell Transplantation. 2003.
7. Auerbach AD. Fanconi anemia diagnosis and the diepoxybutane (DEB) test [editorial]. Exp Hematol. 1993;21:731-733.
8. Cervenka J, Arthur D, Yasis C. Mitomycin C test for diagnostic differentiation of idiopathic aplastic anemia and Fanconi anemia. Pediatrics. 1981;67:119-127.
9. Meetei AR, de Winter JP, Medhurst AL, et al. A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet. 2003;35:165-170.
10. Levitus M, Rooimans MA, Steltenpool J, et al. Heterogeneity in Fanconi anemia: evidence for 2 new genetic subtypes. Blood. 2004;103:2498-2503.
11. Garcia-Higuera I, Taniguchi T, Ganesan S, et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell. 2001;7:249-262.
12. Shimamura A, de Oca RM, Svenson JL, et al. A novel diagnostic screen for defects in the Fanconi anemia pathway. Blood. 2002;100:4649-4654.
13. Howlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 2002;297:606-609.
14. Yang H, Jeffrey PD, Miller J, et al. BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science. 2002;297:1837-1848.
15. Davies AA, Masson JY, McIlwraith MJ, et al. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell. 2001;7:273-282.
16. Marmorstein LY, Ouchi T, Aaronson SA. The BRCA2 gene product functionally interacts with p53 and RAD51. Proc Natl Acad Sci U S A. 1998;95:13869-13874.
17. Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell. 2001;7:263-272.
18. Faivre L, Guardiola P, Lewis C, et al. Association of complementation group and mutation type with clinical outcome in fanconi anemia. Blood. 2000;96:4064-4070.
19. Cohen MM, Levy HP. Chromosome instability syndromes. Adv Hum Genet. 1989;18:43-149,365-371.
20. Kutler DI, Auerbach AD, Satagopan J, et al. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg. 2003;129:106-112.
21. Mitelman F, Kager S. An International System for Human Cytogenetic Nomenclature. ISCN. 1995.
22. Pulsipher M, Kupfer GM, Naf D, et al. Subtyping analysis of Fanconi anemia by immunoblotting and retroviral gene transfer. Mol Med. 1998;4:468-479.
23. Hirsch B, Berry S, Bostrom B, Sencer S. Constitutional chromosomal instability and predisposition to childhood solid tumors: a new syndrome [abstract]. Am J Hum Genet. 1999;65:A63.
24. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst. 1999;91:1310-1316.
25. Schroeder TM, Kurth R. Spontaneous chromosomal breakage and high incidence of leukemia in inherited disease. Blood. 1971;37:96-112.
26. Bigelow SB, Rary JM, Bender MA. G2 chromosomal radiosensitivity in Fanconi's anemia. Mutat Res. 1979;63:189-199.
27. Duckworth-Rysiecki G, Hulten M, Mann J, Taylor AM. Clinical and cytogenetic diversity in Fanconi's anaemia. J Med Genet. 1984;21:197-203.
28. Marcou Y, D'Andrea A., Jeggo PA, Plowman PN. Normal cellular radiosensitivity in an adult Fanconi anaemia patient with marked clinical radiosensitivity. Radiother Oncol. 2001;60:75-79.
29. Gatti RA. The inherited basis of human radiosensitivity. Acta Oncol. 2001;40:702-711.
30. Alter BP. Radiosensitivity in Fanconi's anemia patients. Radiother Oncol. 2002;62:345-347.
31. Brunn D, Folias A, Akkari YM, Cox Y, Olson S, Moses R. siRNA depletion of BRCA1, but not BRCA2, causes increased genome instability in Fanconi anemia cells. DNA Repair, 2003;2:1007-1013.
32. Hussain S, Witt E, Huber PA, Medhurst AL, Ashworth A, Mathew CG. Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1. Hum Mol Genet. 2003;12:2503-2510.
33. de Chadarevian JP, Vekemans M, Bernstein M. Fanconi's anemia, medulloblastoma, Wilms' tumor, horseshoe kidney, and gonadal dysgenesis. Arch Pathol Lab Med. 1985;109:367-369.
34. Ruud E, Wesenberg F. Microcephalus, medulloblastoma and excessive toxicity from chemotherapy: an unusual presentation of Fanconi anaemia. Acta Paediatr. 2001;90:580-583.
35. Offit K, Levran O, Mullaney B, et al. Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst. 2003;95:1548-1551.
36. Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with Fanconi anemia. Blood. 2003;101:822-826.
37. Ikeda H, Matsushita M, Waisfisz Q, et al. Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2. Cancer Res. 2003;63:2688-2694.
38. Begg CB. On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst. 2002;94:1221-1226.